CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 148 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.79 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,410,680 | +33.1% | 94,613 | -2.3% | 0.00% | +100.0% |
| Q2 2023 | $1,060,234 | +63.4% | 96,825 | +30.2% | 0.00% | 0.0% |
| Q1 2023 | $648,690 | +484.4% | 74,391 | +109.0% | 0.00% | – |
| Q1 2022 | $111,000 | -14.0% | 35,601 | -6.6% | 0.00% | – |
| Q4 2021 | $129,000 | -5.1% | 38,109 | +2.2% | 0.00% | – |
| Q3 2021 | $136,000 | -67.4% | 37,301 | -61.0% | 0.00% | -100.0% |
| Q2 2021 | $417,000 | -12.0% | 95,709 | -8.4% | 0.00% | 0.0% |
| Q1 2021 | $474,000 | -21.3% | 104,450 | -0.5% | 0.00% | 0.0% |
| Q4 2020 | $602,000 | -20.8% | 104,923 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $760,000 | +107.7% | 104,923 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $366,000 | +149.0% | 104,923 | +5.7% | 0.00% | – |
| Q1 2020 | $147,000 | -32.3% | 99,290 | -10.5% | 0.00% | – |
| Q4 2019 | $217,000 | -60.0% | 110,967 | +4.6% | 0.00% | -100.0% |
| Q3 2019 | $543,000 | -28.5% | 106,055 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $759,000 | -37.4% | 106,055 | +16.2% | 0.00% | -50.0% |
| Q1 2019 | $1,212,000 | +69.0% | 91,252 | +0.2% | 0.00% | 0.0% |
| Q4 2018 | $717,000 | -28.2% | 91,047 | +1.0% | 0.00% | 0.0% |
| Q3 2018 | $999,000 | -17.4% | 90,176 | -0.0% | 0.00% | -33.3% |
| Q2 2018 | $1,210,000 | – | 90,181 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |